Achieve Life Sciences Q3 net loss widens

Achieve Life Sciences

06/11/2025 12:31

Overview

Achieve Q3 net loss and EPS missed analyst expectations

FDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026

Awarded FDA Commissioner's National Priority Voucher for vaping cessation

Outlook

Company confirms PDUFA action date for cytisinicline as June 20, 2026

Achieve awarded FDA Priority Voucher for vaping cessation

Company highlights unmet need in vaping cessation market

Result Drivers

Total operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectively

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
Miss
-$0.28
-$0.26 (7 Analysts)
Q3 Net Income
Miss
-$14.44 mln
-$12.20 mln (7 Analysts)
Q3 Income From Operations
Miss
-$14.69 mln
-$12.10 mln (7 Analysts)
Q3 Operating Expenses
$14.69 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93

Press Release: ID:nGNX9Y7NHV

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)